Cardioprotection with Yet Another SGLT2 Inhibitor — An Embarrassment of Riches

Evidence for the cardiovascular benefits of sodium–glucose cotransporter 2 (SGLT2) inhibitors continues to accumulate. Most recently, Bhatt et al. performed two randomized trials to investigate the...